With 18.7% of eligible adults reporting being up to date on lung cancer screening in a national survey, this was estimated to ...
Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback